查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439634

體外診斷 - 全球市場考量、競爭狀況、市場預測 (2030)

In Vitro Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按訂單生產 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

全球體外診斷市場規模將於 2023 年達到 710.1 億美元，到 2030 年將達到 936 億美元，預計在 2024-2030 年預測期內複合年增長率為 4.71%。 該市場受到 COVID-19 等各種傳染病患者病率上升、各種癌症患病率上升、血液疾病病例上升以及體外診斷產品開發活動增加等因素的推動，預計將錄得正收入增長。

體外診斷市場動態

體外診斷市場的主要驅動因素之一是 COVID-19 大流行的爆發以及迫切需要診斷測試來遏制 COVID-19 的傳播。 根據世界衛生組織（WHO）編製的最新數據，截至 2022 年 11 月，全球共有 255,324,963 例確診的 COVID-19 病例，其中 5,127,696 人死亡。 SARS-COV-2病毒的高毒力引起了世界各地的恐慌，並導致世界不同地區採取了不同階段的封鎖措施。 這迫切需要檢測 SARS-COV-2 病毒的診斷方法和試劑盒，以便為感染者和未感染者提供更好的治療。 技術的進步導致了許多逆轉錄酶聚合酶鍊式反應測試和快速抗原測試的發展，滿足了對新的可靠診斷試劑盒的需求，以應對大流行造成的緊急情況，這將延長預測期限。對體外診斷市場的成長產生正面影響。

除了 COVID-19 大流行之外，促進體外診斷市場成長的另一個因素是肺癌等各種癌症的盛行率不斷上升。 根據世界衛生組織引用的 GLOBOCAN (2020) 研究，2020 年，肺癌是第二常見癌症，全球新增病例 2,206,771 例。 此外，肺癌是所有癌症類型中導致死亡的主要原因，全世界有 1,796,144 人死亡。 體外診斷為癌症的早期診斷提供了機會，從而為患者帶來更好的臨床結果。

產品開發的技術進步和對癌症研究的深入瞭解導致了液體活檢的發展。 該技術屬於體外診斷的分子診斷分支，並已被證明在組織活檢不可行的癌症診斷中具有價值。 此外，液體切片不僅可用於癌症診斷，還可用作伴隨診斷設備，幫助評估患者特定治療介入措施的有效性。 因此，由於癌症盛行率不斷增加，需要能夠改善癌症診斷和管理的體外診斷儀器和產品。 因此，肺癌盛行率的上升、體外診斷在肺癌診斷和治療方面的優勢可能會導致對體外診斷產品的需求增加，並支持預測期內體外診斷市場的成長。

然而，開發準確的診斷測試和設備的挑戰以及有關產品審批的嚴格規定可能會限制體外診斷市場的成長。

此外，COVID-19大流行的影響增加了對各種自我監測和檢測試劑盒和產品以及COVID-19特定檢測的需求，導致體外診斷的收入急劇增加市場。 由於 COVID-19 病毒的傳染性，診斷學非常需要製定限制病毒傳播的策略。 隨著COVID-19株的分離及其基因組序列的鑑定，市面上出現了多種COVID-19檢測試劑盒，以滿足患者和醫護人員的各種需求。 因此，預計體外診斷市場在 COVID-19 大流行期間將呈現正成長率。

體外診斷市場細分分析

在體外診斷市場的測試類型領域，分子診斷類別預計在預測期內將顯著增長。 這是由於分子診斷由於其相關優勢而在臨床實踐中日益普及。 分子診斷被認為是臨床診斷中更敏感的方法，可以檢測到較小滴度的傳染原，可能比以前更快地檢測出感染。 這對於疾病的早期診斷非常重要，可以改善患者的預後。

本報告提供了全球體外診斷市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

目錄

第1章體外診斷市場報告簡介

第 2 章體外診斷市場執行摘要

  • 調查範圍
  • 市場概覽
  • 競爭評估
  • 財務基準

第3章監理與專利分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章體外診斷市場關鍵因素分析

  • 體外診斷市場驅動因素
    • 新冠肺炎 (COVID-19) 等傳染病的流行
    • 癌症盛行率不斷上升
    • 血液疾病盛行率不斷上升
    • 產品開發方面的技術進步
  • 體外診斷市場的限制與挑戰
    • 開發準確的診斷測試和設備面臨的挑戰
    • 有關產品核准的嚴格規定
  • 體外診斷市場機遇
    • 改進產品設計
    • 推出針對新興市場的產品

第5章體外診斷市場波特五力分析

第6章 COVID-19 對體外診斷市場的影響分析

第7章體外診斷市場佈局

  • 依產品類型
    • 設備
    • 試劑
    • 其他
  • 按檢定類型
    • 免疫診斷
    • 血
    • 分子診斷
    • 臨床化學
  • 依用途
    • 腫瘤
    • 免疫
    • 傳染病
    • 心
    • 腎臟
  • 按最終用戶
    • 醫院
    • 診斷實驗室
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他領域

第 8 章體外診斷市場：全球公司佔有率分析 - 主要 3 至 5 家公司

第 9 章體外診斷市場公司與產品概況

  • F. Hoffmann-La Roche Ltd
  • Abbott
  • FUJIFILM Corporation
  • Sysmex Corporation
  • Siemens Healthcare GmbH
  • BD
  • Seegene Inc
  • Beckman Coulter, Inc (Danaher Corporation)
  • QIAGEN
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc
  • Thermo Fisher Scientific Inc
  • Cisbio (PerkinEemer)
  • ARKRAY, Inc
  • Ortho Clinical Diagnostics
  • ACON Laboratories, Inc
  • Teco Diagnostics
  • EKF Diagnostics
  • Besurence GmbH
  • Savyon Diagnostics
  • HORIBA, Ltd
  • Palliance AB
  • Sugentech, Inc
  • Cypress Diagnostics
  • Salignostics
  • The Menarini Group
  • DxGen Corp.
  • HUMAN
  • Nova Medical
  • Asahi Kasei Pharma Corporation
  • Agilent Technologies, Inc

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

Product Code: DIMDCL0470

In-Vitro Diagnostics Market By Prodcut Type (Instruments, Reagents, And Others), By Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, And Others), By Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, And Others) By End User (Hospitals, Diagnostic Laboratries, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of various infectious diseases such as COVID-19 infection and cancers such as lung cancer.

Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030. The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.

In Vitro Diagnostics Market Dynamics:

One of the major drivers of the in vitro diagnostics market was the onset of the COVID-19 pandemic and the urgency felt for the need of the diagnostic tests in order to contain the spread of the COVID-19 infection. As per the latest data collated by the World Health Organization (WHO), as of November 2022, there have been 255,324,963 confirmed cases of COVID-19, including 5,127,696 deaths across the globe. The high virulence associated with the SARS- COV-2 virus led to panic situation across the globe and led to various stages of lockdowns globally. This led to the exigent need for diagnostic methods and kits for the detection of the SARS-COV-2 virus with the aim to design better care for both infected and uninfected population groups. Technological advancements led to the development of numerous reverse transcriptase polymerase chain reaction tests as well as rapid antigen tests in order to serve the need for reliable novel diagnostic kits to meet the urgency created by the pandemic thereby positively impacting the in vitro diagnostics market growth during the forecast period.

Besides COVID-19 pandemic, another contributing factor responsible in the growth of the in vitro diagnostics market is the rising prevalence of various cancers such as lung cancer. As per the facts stated by the GLOBOCAN 2020 study cited by the WHO, in 2020, lung cancer was the second most diagnosed cancer type with 2,206,771 new cases across the globe. In addition to that, lung cancer was the leading cause of death among all cancer types accounting for 1,796,144 deaths globally. In vitro diagnostics provide an opportunity for early diagnosis of cancer thereby providing better clinical outcomes for patients.

Technological advancements in product development coupled with better understanding in cancer research led to the development of liquid biopsy. This technique comes under the molecular diagnostics branch of in vitro diagnostics and has proven to be beneficial in cancer diagnosis where tissue biopsy proved to be unfeasible. Moreover, besides helping in cancer diagnosis, liquid biopsy has also been used in the companion diagnostic device which helps in assessing the efficacy of a particular therapeutic intervention in a patient. Therefore, the rising prevalence of cancers have necessitated the need for in vitro diagnostic devices and products for improving cancer diagnosis and management. Hence, the rising prevalence of lung cancer as well as benefits of in vitro diagnostics in lung cancer diagnosis and treatment may contribute in the rising demand for in vitro diagnostic products, thereby supporting the growth of the in vitro diagnostics market during the forecast period.

However, challenges in the development of accurate diagnostic tests and equipment and stringent regulations regarding product approvals may hinder the IVD market growth.

Moreover, the impact of the COVID-19 pandemic resulted in the surge in revenue for the in vitro diagnostics market due to the growing demand for COVID-19-specific tests as well as various self-monitoring and testing kits and products. Owing to the contagious nature of the COVID-19 virus, there was a huge need for diagnostic methods in order to devise strategies for the containment of the viral spread. With the isolation and the identification of genomic sequence of the COVID-19 strain, several COVID-19 test kits made it to the market to cater to different requirements of patients and healthcare workers. Therefore, the market for in vitro diagnostics was expected to witness a positive growth rate during the COVID-19 pandemic.

In Vitro Diagnostics Market Segment Analysis:

In-Vitro Diagnostics Market by Product Type (Instruments, Reagents, and Others), by Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, and Others), by Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, and Others) by End User (Hospitals, Diagnostic Laboratories, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the test type segment of the in vitro diagnostics market, the molecular diagnostics category is expected to register significant growth during the forecast period. This can be attributed to the growing popularity of molecular diagnostics in clinical settings due to advantages associated with them. Molecular diagnostics is considered as a more sensitive method in clinical diagnosis and allows for the detection of even smaller titers of infectious pathogens, thus offering the possibility of detecting infections faster than before. This is extremely important in terms of early disease diagnosis and thereby improving the prognosis for patient.

Furthermore, technological advancements have led to the development of innovative molecular diagnostic techniques such as liquid biopsy which has proven to aid in cancer diagnosis and management as they can provide comprehensive information on the molecular landscapes of different cancers such as non-small cell lung cancer and can also provide insights into approaches to overcome tumor heterogeneity and monitor tumors in real time.

Therefore, considering the advantages associated with molecular diagnostics, this product category is expected to generate significant revenue share eventually contributing the overall growth of the global in vitro diagnostics market during the forecast period.

Asia-Pacific is expected to register fastest growth the Overall In Vitro Diagnostics Market:

Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers, growing geriatric population along with rising hematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.

One of the key driving factors of the APAC in vitro diagnostics market is the high prevalence of anemia in the region. As per the latest data provided the World Health Organization (2023), out of the global prevalent population of anemia in non-pregnant women (539,000), South-East Asia accounted for the highest regional anemic non-pregnant female population (age group- 15-49) with 234,000 people. The source further stated that in 2019, India and China registered approximately 758,200 and 190,400 cases of anemia in pregnant women. Anemia is widespread throughout the world and affects children and women of childbearing age. Anemia is associated with motor and cognitive development and diminished work capacity. In pregnant women, iron deficiency anemia is also associated with adverse reproductive effects such as preterm birth, low birth weight infants, and reduced iron storage in babies, which can lead to developmental disorders. IVDs are considered as an essential component in primary healthcare and is highly utilized in hematology-related tests for hemoglobin, white blood cell among others. Therefore, the rising prevalence of anemia in the region is expected to drive the demand for IVDs, which in turn would provide a conducive growth environment for the Asia-Pacific IVD market.

Moreover, the large presence of diabetic population in the APAC region is also a key factor stimulating the demand for in vitro diagnostic products in the region. This can be supported by the facts provided by the International Diabetes Federation. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults in the age group of 20-79 years were living with diabetes in the South-East Asia region in 2019. As per the data provided by the IDF, in 2019, China had the highest number of diabetics worldwide, with 116 million people with diabetes, which was followed by India (77 million people with diabetes). Furthermore, the factsheet by the WHO also states that the prevalence of diabetes has been higher in developing economies than in developed nations. In vitro diagnostics has been extremely beneficial for diabetes monitoring as the need for constant monitoring of glycemic levels has led to the development of numerous blood glucose self-monitoring products such as AccuChek and other products. Therefore, the rising prevalence of diabetes in the region is predicted to boost the APAC in vitro diagnostics market in the coming years.

In Vitro Diagnostics Market Key Players:

Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.

Recent Developmental Activities in In Vitro Diagnostics Market:

In October 2022, Bio-Rad Laboratories, Inc launched their CFX Dx Real-Time PCR Detection systems- CFX(TM) Opus 96 Dx System and the CFX(TM) Opus 384 Dx System for In Vitro Diagnostics.

In March 2022, Agilent Technologies Inc announced the launch of the eal-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA in the European markets after completing the registration of the product in accordance with the European Union regulations thereby receiving the CE-IVD mark.

In March 2022, Roche announced the launch of connected glucose monitoring system- the new Accu-Chek Instant system compatible with integrated Personalized Diabetes Management (iPDM).

Key Takeaways from the In Vitro Diagnostics Market Report Study

Market size analysis for current in vitro diagnostics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the in vitro diagnostics market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global in vitro diagnostics market.

Various opportunities available for the other competitor in the in vitro diagnostics market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current in vitro diagnostics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for in vitro diagnostics market growth in the coming future?

Target Audience who can be benefited from this In Vitro Diagnostics Market Report Study

In Vitro Diagnostics products providers

Research organizations and consulting companies

In Vitro Diagnostics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in in vitro diagnostics

Various End-users who want to know more about the in vitro diagnostics market and latest technological developments in the in vitro diagnostics market.

Frequently Asked Questions for In Vitro Diagnostics Market:

1. What is an In Vitro Diagnostic Device?

In vitro diagnostic products are classified as product such as instruments, systems, and reagents intended to be used in the diagnosis, monitoring, planning for treatment of disease or other conditions.

2. What is the Global market for In Vitro Diagnostics?

Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030.

3. What are the drivers for Global In Vitro Diagnostics Market?

The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of haematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.

4. Who are the key players operating in Global In Vitro Diagnostics Market?

Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.

5. Which region is expected to register fastest growth in In Vitro Diagnostics Market?

Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers including lung cancers, growing geriatric population along with rising haematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.

Table of Contents

1.In Vitro Diagnostics Market Report Introduction

2.In Vitro Diagnostics Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. In Vitro Diagnostics Market Key Factors Analysis

  • 4.1 In Vitro Diagnostics Market Drivers
    • 4.1.1 Increasing Prevalence of Infectious Diseases such as COVID-19 Infection
    • 4.1.2 Rising Prevalence of Cancers
    • 4.1.3 Growing Prevalence of Hematological Diseases
    • 4.1.4 Technological Advancements in Product Development
  • 4.2 In Vitro Diagnostics Market Restraints and Challenges
    • 4.2.1 Challenges in The Development of Accurate Diagnostic Tests and Equipment
    • 4.2.2 Stringent Regulations Regarding Product Approvals
  • 4.3 In Vitro Diagnostics Market Opportunities
    • 4.3.1 Improving on the Product Design
    • 4.3.2 Targeting Emerging Markets for Product Launches

5. In Vitro Diagnostics Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on In Vitro Diagnostics Market

7. In Vitro Diagnostics Market Layout

  • 7.1 By Product Type
    • 7.1.1 Instruments
    • 7.1.2 Reagents
    • 7.1.3 Others
  • 7.2 By Test Type
    • 7.2.1 Immunodiagnostics
    • 7.2.2 Hematology
    • 7.2.3 Molecular Diagnostics
    • 7.2.4 Clinical Chemistry
    • 7.2.5 Others
  • 7.3 By Application
    • 7.3.1 Oncology
    • 7.3.2 Immunology
    • 7.3.3 Infectious Diseases
    • 7.3.4 Cardiology
    • 7.3.5 Nephrology
    • 7.3.6 Others
  • 7.4 By End User
    • 7.4.1 Hospitals
    • 7.4.2 Diagnostic Laboratories
    • 7.3.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 North America In Vitro Diagnostics Market, by Product Type
      • 7.5.1.2 North America In Vitro Diagnostics Market, by Test Type
      • 7.5.1.3 North America In Vitro Diagnostics Market, by Application
      • 7.5.1.4 North America In Vitro Diagnostics Market, by End User
      • 7.5.1.5 North America In Vitro Diagnostics Market, by Country
      • 7.5.1.3.1 United States
      • 7.5.1.3.2 Canada
      • 7.5.1.3.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 Europe In Vitro Diagnostics Market, by Product Type
      • 7.5.2.2 Europe In Vitro Diagnostics Market, by Test Type
      • 7.5.2.3 Europe In Vitro Diagnostics Market, by Application
      • 7.5.2.4 Europe In Vitro Diagnostics Market, by End User
      • 7.5.2.5 Europe In Vitro Diagnostics Market, by Country
      • 7.5.2.3.1 France
      • 7.5.2.3.2 Germany
      • 7.5.2.3.3 United Kingdom
      • 7.5.2.3.4 Italy
      • 7.5.2.3.5 Spain
      • 7.5.2.3.6 Russia
      • 7.5.2.3.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 Asia-Pacific In Vitro Diagnostics Market, by Product Type
      • 7.5.3.2 Asia-Pacific In Vitro Diagnostics Market, by Test Type
      • 7.5.3.3 Asia-Pacific In Vitro Diagnostics Market, by Application
      • 7.5.3.4 Asia-Pacific In Vitro Diagnostics Market, by End User
      • 7.5.3.5 Asia-Pacific In Vitro Diagnostics Market, by Country
      • 7.5.3.3.1 China
      • 7.5.3.3.2 Japan
      • 7.5.3.3.3 India
      • 7.5.3.3.4 Australia
      • 7.5.3.3.5 South Korea
      • 7.5.3.3.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 RoW In Vitro Diagnostics Market, by Product Type
      • 7.5.4.2 RoW In Vitro Diagnostics Market, by Test Type
      • 7.5.4.3 RoW In Vitro Diagnostics Market, by Application
      • 7.5.4.4 RoW In Vitro Diagnostics Market, by End User
      • 7.5.4.5 RoW In Vitro Diagnostics Market, by Region
      • 7.5.4.3.1 Middle East
      • 7.5.4.3.2 Africa
      • 7.5.4.3.3 South America

8. In Vitro Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. In Vitro Diagnostics Market Company and Product Profiles

  • 9.1 F. Hoffmann-La Roche Ltd
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Abbott
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 FUJIFILM Corporation
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Sysmex Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Siemens Healthcare GmbH
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 BD
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Seegene Inc
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 Beckman Coulter, Inc (Danaher Corporation)
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 QIAGEN
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 bioMerieux SA
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 Bio-Rad Laboratories, Inc
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 Thermo Fisher Scientific Inc
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Cisbio (PerkinEemer)
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 ARKRAY, Inc
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 Ortho Clinical Diagnostics
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 ACON Laboratories, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Teco Diagnostics
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 EKF Diagnostics
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 Besurence GmbH
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 Savyon Diagnostics
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy
  • 9.21 HORIBA, Ltd
    • 9.21.1. Company Overview
    • 9.21.2. Company Snapshot
    • 9.21.3. Financial Overview
    • 9.21.4 Product Listing
    • 9.21.5. Entropy
  • 9.22 Palliance AB
    • 9.22.1. Company Overview
    • 9.22.2. Company Snapshot
    • 9.22.3. Financial Overview
    • 9.22.4 Product Listing
    • 9.22.5. Entropy
  • 9.23 Sugentech, Inc
    • 9.23.1. Company Overview
    • 9.23.2. Company Snapshot
    • 9.23.3. Financial Overview
    • 9.23.4 Product Listing
    • 9.23.5. Entropy
  • 9.24 Cypress Diagnostics
    • 9.24.1. Company Overview
    • 9.24.2. Company Snapshot
    • 9.24.3. Financial Overview
    • 9.24.4 Product Listing
    • 9.24.5. Entropy
  • 9.25 Salignostics
    • 9.25.1. Company Overview
    • 9.25.2. Company Snapshot
    • 9.25.3. Financial Overview
    • 9.25.4 Product Listing
    • 9.25.5. Entropy
  • 9.26 The Menarini Group
    • 9.26.1. Company Overview
    • 9.26.2. Company Snapshot
    • 9.26.3. Financial Overview
    • 9.26.4 Product Listing
    • 9.26.5. Entropy
  • 9.27 DxGen Corp.
    • 9.27.1. Company Overview
    • 9.27.2. Company Snapshot
    • 9.27.3. Financial Overview
    • 9.27.4 Product Listing
    • 9.27.5. Entropy
  • 9.28 HUMAN
    • 9.28.1. Company Overview
    • 9.28.2. Company Snapshot
    • 9.28.3. Financial Overview
    • 9.28.4 Product Listing
    • 9.28.5. Entropy
  • 9.29 Nova Medical
    • 9.29.1. Company Overview
    • 9.29.2. Company Snapshot
    • 9.29.3. Financial Overview
    • 9.29.4 Product Listing
    • 9.29.5. Entropy
  • 9.30 Asahi Kasei Pharma Corporation
    • 9.30.1. Company Overview
    • 9.30.2. Company Snapshot
    • 9.30.3. Financial Overview
    • 9.30.4 Product Listing
    • 9.30.5. Entropy
  • 9.31 Agilent Technologies, Inc
    • 9.31.1. Company Overview
    • 9.31.2. Company Snapshot
    • 9.31.3. Financial Overview
    • 9.31.4 Product Listing
    • 9.31.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis
  • Table 3 In Vitro Diagnostics Market in Global (2021-2030)
  • Table 4 In Vitro Diagnostics Market in Global by Product Type (2021-2030)
  • Table 5 In Vitro Diagnostics Market in Global by Test Type (2021-2030)
  • Table 6 In Vitro Diagnostics Market in Global by Application (2021-2030)
  • Table 7 In Vitro Diagnostics Market in Global by End User (2021-2030)
  • Table 8 In Vitro Diagnostics Market in Global by Geography (2021-2030)
  • Table 9 In Vitro Diagnostics Market in North America (2021-2030)
  • Table 10 In Vitro Diagnostics Market in North America by Product Type (2021-2030)
  • Table 11 In Vitro Diagnostics Market in North America by Test Type (2021-2030)
  • Table 12 In Vitro Diagnostics Market in North America by Application (2021-2030)
  • Table 13 In Vitro Diagnostics Market in North America by End User (2021-2030)
  • Table 14 In Vitro Diagnostics Market in North America by Country (2021-2030)
  • Table 15 In Vitro Diagnostics Market in the US (2021-2030)
  • Table 16 In Vitro Diagnostics Market in Canada (2021-2030)
  • Table 17 In Vitro Diagnostics Market in Mexico (2021-2030)
  • Table 18 In Vitro Diagnostics Market in Europe (2021-2030)
  • Table 19 In Vitro Diagnostics Market in Europe by Product Type (2021-2030)
  • Table 20 In Vitro Diagnostics Market in Europe by Test Type (2021-2030)
  • Table 21 In Vitro Diagnostics Market in Europe by Application (2021-2030)
  • Table 22 In Vitro Diagnostics Market in Europe by End User (2021-2030)
  • Table 23 In Vitro Diagnostics Market in Europe by Country (2021-2030)
  • Table 24 In Vitro Diagnostics Market in France (2021-2030)
  • Table 25 In Vitro Diagnostics Market in Germany (2021-2030)
  • Table 26 In Vitro Diagnostics Market in the United Kingdom (2021-2030)
  • Table 27 In Vitro Diagnostics Market in Italy (2021-2030)
  • Table 28 In Vitro Diagnostics Market in Spain (2021-2030)
  • Table 29 In Vitro Diagnostics Market in Russia (2021-2030)
  • Table 30 In Vitro Diagnostics Market in Rest of Europe (2021-2030)
  • Table 31 In Vitro Diagnostics Market in APAC (2021-2030)
  • Table 32 In Vitro Diagnostics Market in APAC by Product Type (2021-2030)
  • Table 33 In Vitro Diagnostics Market in APAC by Test Type (2021-2030)
  • Table 34 In Vitro Diagnostics Market in APAC by Application (2021-2030)
  • Table 35 In Vitro Diagnostics Market in APAC by End User (2021-2030)
  • Table 36 In Vitro Diagnostics Market in APAC by Country (2021-2030)
  • Table 37 In Vitro Diagnostics Market in China (2021-2030)
  • Table 38 In Vitro Diagnostics Market in Japan (2021-2030)
  • Table 39 In Vitro Diagnostics Market in India (2021-2030)
  • Table 40 In Vitro Diagnostics Market in Australia (2021-2030)
  • Table 41 In Vitro Diagnostics Market in South Korea (2021-2030)
  • Table 42 In Vitro Diagnostics Market in Rest of APAC (2021-2030)
  • Table 43 In Vitro Diagnostics Market in Rest of World (2021-2030)
  • Table 44 In Vitro Diagnostics Market in RoW by Product Type (2021-2030)
  • Table 45 In Vitro Diagnostics Market in RoW by Test Type (2021-2030)
  • Table 46 In Vitro Diagnostics Market in RoW by Application (2021-2030)
  • Table 47 In Vitro Diagnostics Market in RoW by End User (2021-2030)
  • Table 48 In Vitro Diagnostics Market in RoW by Region (2021-2030)
  • Table 49 In Vitro Diagnostics Market in Middle East (2021-2030)
  • Table 50 In Vitro Diagnostics Market in Africa (2021-2030)
  • Table 51 In Vitro Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis
  • Figure 3 In Vitro Diagnostics Market in Global (2021-2030)
  • Figure 4 In Vitro Diagnostics Market in Global by Product Type (2021-2030)
  • Figure 5 In Vitro Diagnostics Market in Global by Test Type (2021-2030)
  • Figure 6 In Vitro Diagnostics Market in Global by Application (2021-2030)
  • Figure 7 In Vitro Diagnostics Market in Global by End User (2021-2030)
  • Figure 8 In Vitro Diagnostics Market in Global by Geography (2021-2030)
  • Figure 9 In Vitro Diagnostics Market in North America (2021-2030)
  • Figure 10 In Vitro Diagnostics Market in North America by Product Type (2021-2030)
  • Figure 11 In Vitro Diagnostics Market in North America by Test Type (2021-2030)
  • Figure 12 In Vitro Diagnostics Market in North America by Application (2021-2030)
  • Figure 13 In Vitro Diagnostics Market in North America by End User (2021-2030)
  • Figure 14 In Vitro Diagnostics Market in North America by Country (2021-2030)
  • Figure 15 In Vitro Diagnostics Market in the US (2021-2030)
  • Figure 16 In Vitro Diagnostics Market in Canada (2021-2030)
  • Figure 17 In Vitro Diagnostics Market in Mexico (2021-2030)
  • Figure 18 In Vitro Diagnostics Market in Europe (2021-2030)
  • Figure 19 In Vitro Diagnostics Market in Europe by Product Type (2021-2030)
  • Figure 20 In Vitro Diagnostics Market in Europe by Test Type (2021-2030)
  • Figure 21 In Vitro Diagnostics Market in Europe by Application (2021-2030)
  • Figure 22 In Vitro Diagnostics Market in Europe by End User (2021-2030)
  • Figure 23 In Vitro Diagnostics Market in Europe by Country (2021-2030)
  • Figure 24 In Vitro Diagnostics Market in France (2021-2030)
  • Figure 25 In Vitro Diagnostics Market in Germany (2021-2030)
  • Figure 26 In Vitro Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 27 In Vitro Diagnostics Market in Italy (2021-2030)
  • Figure 28 In Vitro Diagnostics Market in Spain (2021-2030)
  • Figure 29 In Vitro Diagnostics Market in Russia (2021-2030)
  • Figure 30 In Vitro Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 31 In Vitro Diagnostics Market in APAC (2021-2030)
  • Figure 32 In Vitro Diagnostics Market in APAC by Product Type (2021-2030)
  • Figure 33 In Vitro Diagnostics Market in APAC by Test Type (2021-2030)
  • Figure 34 In Vitro Diagnostics Market in APAC by Application (2021-2030)
  • Figure 35 In Vitro Diagnostics Market in APAC by End User (2021-2030)
  • Figure 36 In Vitro Diagnostics Market in APAC by Country (2021-2030)
  • Figure 37 In Vitro Diagnostics Market in China (2021-2030)
  • Figure 38 In Vitro Diagnostics Market in Japan (2021-2030)
  • Figure 39 In Vitro Diagnostics Market in India (2021-2030)
  • Figure 40 In Vitro Diagnostics Market in Australia (2021-2030)
  • Figure 41 In Vitro Diagnostics Market in South Korea (2021-2030)
  • Figure 42 In Vitro Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 43 In Vitro Diagnostics Market in Rest of World (2021-2030)
  • Figure 44 In Vitro Diagnostics Market in RoW by Product Type (2021-2030)
  • Figure 45 In Vitro Diagnostics Market in RoW by Test Type (2021-2030)
  • Figure 46 In Vitro Diagnostics Market in RoW by Application (2021-2030)
  • Figure 47 In Vitro Diagnostics Market in RoW by End User (2021-2030)
  • Figure 48 In Vitro Diagnostics Market in RoW by Region (2021-2030)
  • Figure 49 In Vitro Diagnostics Market in Middle East (2021-2030)
  • Figure 50 In Vitro Diagnostics Market in Africa (2021-2030)
  • Figure 51 In Vitro Diagnostics Market in South America (2021-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Marker Opportunities
  • Figure 55 PORTER'S Five Force Analysis